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The increasing number of pathogens expressing metallo--lactamases (MBLs),
and in this way achieving resistance to -lactam antibiotics, is a significant threat
to global public health. A promising strategy to treat such resistant pathogens is
the co-administration of MBL inhibitors together with -lactam antibiotics.
However, an MBL inhibitor suitable for clinical use has not yet been identified.
Verona integron-encoded metallo--lactamase 2 (VIM-2) is a widespread MBL
with a broad substrate spectrum and hence is an interesting drug target for the
treatment of -lactam-resistant infections. In this study, three triazolylthio-
acetamides were tested as inhibitors of VIM-2. One of the tested compounds
showed clear inhibition of VIM-2, with an IC50 of 20 mM. The crystal structure
of the inhibitor in complex with VIM-2 was obtained by DMSO-free co-
crystallization and was solved at a resolution of 1.50 Å. To our knowledge, this is
the first structure of a triazolylthioacetamide inhibitor in complex with an MBL.
Analysis of the structure shows that the inhibitor binds to the two zinc ions in
the active site of VIM-2 and revealed detailed information on the interactions
involved. Furthermore, the crystal structure showed that binding of the inhibitor
induced a conformational change of the conserved residue Trp87.
1. Introduction
The discovery of -lactam antibiotics for the treatment of
bacterial infections has revolutionized modern medicine and
saved countless lives. Unfortunately, the overuse of these
antibiotics has resulted in the rapid emergence of -lactam-
resistant bacteria, representing a major threat to global public
health (World Health Organization, 2014). A main mechanism
for bacteria to develop resistance to -lactam antibiotics is the
expression of -lactamases, enzymes that are able to hydrolyse
the -lactam ring and render the antibiotics ineffective. The
co-administration of -lactamase inhibitors together with
-lactam antibiotics can prevent their hydrolysis and in this
way overcome resistance. To date, two different groups of
-lactamases have been identified: metallo--lactamases
(MBLs) and serine -lactamases (SBLs). For SBLs, potent
inhibitors co-administered with -lactam antibiotics are
already in clinical use (Drawz & Bonomo, 2010; Lucasti et al.,
2016). However, no MBL inhibitors have yet reached clinical
use, and hence there is a clear need to identify novel inhibitors
(Fast & Sutton, 2013).
Verona integron-encoded metallo--lactamase 2 (VIM-2) is
a widespread MBL with a broad substrate spectrum, including
penicillins, cephalosporins, cephamycins and carbapenems
(Poirel et al., 2000). In its mature form, VIM-2 is a monomeric
enzyme consisting of 240 amino acids with a molecular mass
of 25 kDa (Docquier et al., 2003; Garcia-Saez et al., 2008).
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Several crystal structures of VIM-2 have been reported
(Garcia-Saez et al., 2008; Aitha et al., 2014). The structures
show that the enzyme is folded in an / sandwich and that
two zinc ions bridged by a hydroxide are located in the active
site. Furthermore, crystal structures of different inhibitors in
complex with VIM-2 have been reported (Brem et al., 2014,
2016; Christopeit et al., 2015). VIM-2 has a high clinical rele-
vance owing to its wide spread and broad substrate range, and
therefore reflects an important drug target for the treatment
of antibiotic-resistant infections.
Triazolylthioacetamides have been identified as inhibitors
of different MBLs and hence are interesting scaffolds for the
design of potent VIM-2 inhibitors (Zhang et al., 2014; Yang
et al., 2015; Zhai et al., 2016). In this study, we tested three
different substituted triazolylthioacetamides as inhibitors of
VIM-2. Moreover, the complex structure of one of the inhi-
bitors bound to VIM-2 is presented and protein–inhibitor
interactions are explored.
2. Materials and methods
2.1. Expression and purification of VIM-2
The expression and purification of VIM-2 was carried out
as described previously (Christopeit et al., 2015). In brief, the
gene sequence coding for residues Val25–Glu300 of VIM-2
was isolated from Pseudomonas aeruginosa strain 301-5473.
The sequence for a 6His tag and a Tobacco etch virus (TEV)
protease cleavage site was added and the construct was
transferred into pDEST14 vector. Chemically competent
Escherichia coli BL21(DE3)pLysS cells (Invitrogen) were
transformed with the VIM-2 pDEST14 vector and cultured
at 37C in Terrific broth (TB) medium supplemented with
100 mg l1 ampicillin and 34 mg l1 chloramphenicol. Protein
expression was induced overnight at 20C with 0.4 mM
isopropyl -d-1-thiogalactopyranoside (IPTG). The cells were
harvested by centrifugation and stored at 80C. Sonication
was used to lyse the cells and insoluble material was removed
by centrifugation. The supernatant was applied onto a HisTrap
HP column (GE Healthcare) and bound VIM-2 was eluted
with a linear imidazole gradient. The His tag was removed by
adding in-house-produced His-tagged TEV protease. The
cleaved His tag, uncleaved protein and the His-tagged TEV
protease were removed by performing a second HisTrap
purification. The flowthrough containing VIM-2 was collected
and the protein was finally purified by anion-exchange
chromatography. The purity of the enzyme was analysed by
SDS–PAGE and the activity was confirmed by the hydrolysis
of nitrocefin. The protein concentration was determined by
measuring the absorption at 280 nm using a NanoDrop 2000c
spectrophotometer (Thermo Scientific). The extinction coef-
ficient of 29 910 M1 cm1 at 280 nm was estimated from the
amino-acid sequence of VIM-2 using ProtParam (Gasteiger et
al., 2005).
2.2. Synthesis of compounds 1, 2 and 3
Compound 1 was synthesized and characterized as
described previously by Yang et al. (2015) and compounds 2
and 3 as described previously by Zhang et al. (2014). All
compounds were dissolved in DMSO at a concentration of
100 mM and stored at 20C.
2.3. Enzyme-inhibition assay and IC50 determination
The IC50 values were determined using a previously
established enzyme-activity assay based on the hydrolysis
of nitrocefin (Christopeit et al., 2015). Measurements were
carried out at 25C in 96-well plates using a SpectraMax M2e
(Molecular Devices). Data were analysed using the SoftMax
Pro 5.2 software (Molecular Devices) and GraphPad Prism 5
(GraphPad Software). A buffer consisting of 50 mM HEPES
pH 7.2, 150 mM NaCl, 100 mM ZnCl2, 0.005% Tween 20, 2.5%
DMSO and 20 mg ml1 bovine serum albumin (BSA) was used
in all measurements. The inhibitors were dissolved in buffer in
a twofold dilution series and mixed with VIM-2. After 5 min of
incubation, the enzyme reaction was started by adding nitro-
cefin (Calbiochem) to a final concentration of 3 mM. The final
enzyme concentration was 150 pM. The hydrolysis of nitro-
cefin was followed by measurement of the absorption at
482 nm every 17 s for 20 min. The initial velocity was deter-
mined and the percentage of inhibition was calculated in
relation to a positive control without inhibitor. The percentage
of inhibition was plotted against the inhibitor concentration
and the data were fitted to a dose–response curve with a
constant top plateau (100%), a constant bottom plateau (0%)
and a constant Hill slope of 1.
2.4. Crystallization, X-ray data collection and structure
determination
VIM-2 was crystallized by the sitting-drop vapour-diffusion
method (Table 1) using a new DMSO-free co-crystallization
method. The reservoir wells of an MRC 96-well crystallization
plate (Molecular Dimensions) were pre-coated with the inhi-
bitor. 3 ml of compound 1 (100 mM) dissolved in DMSO was
added to every reservoir well and the DMSO was evaporated
by leaving the plate open in a fume hood for 24 h. After
evaporation of the DMSO, 60 ml of reservoir solution was
added consisting of 22–27% polyethylene glycol (PEG) 3350,
0.2 M magnesium formate. The 96-well plate was placed on a
shaker for 24 h to dissolve the inhibitor in the reservoir
solution. The reservoir solution was mixed with the protein
solution (9.4 mg ml1) in a 1:1 ratio and crystals appeared
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Table 1
Crystallization.
Method Sitting-drop vapour diffusion in a new
DMSO-free co-crystallization method
Plate type MRC 96-well crystallization plate
(Molecular Dimensions)
Temperature (C) 22
Protein concentration (mg ml1) 9.4
Buffer composition of protein
solution
50 mM Tris–HCl pH 7.2, 100 mM ZnCl2
Composition of reservoir
solution
22–27% PEG 3350, 0.2 M magnesium
formate
Volume and ratio of drop 2 ml, 1:1
Volume of reservoir 60 ml
after 2–14 d. For cryoprotection, crystals were transferred to
25% PEG 3350, 0.2 M MgCl2, 15% ethylene glycol, 50 mM
HEPES pH 7.2 and were flash-cooled in liquid nitrogen. X-ray
data were collected on beamline BL14.1 operated by the Joint
Berlin MX-Laboratory at the BESSY II electron-storage ring
(Mueller et al., 2012). Statistics for data collection are shown
in Table 2. XDS, POINTLESS and AIMLESS were used to
integrate, scale and truncate the data set and to determine the
space group (Kabsch, 2010; Evans, 2006, 2011; Evans &
Murshudov, 2013). The phase problem was solved by mole-
cular replacement using Phaser (McCoy et al., 2007) and a
previously published VIM-2 structure (PDB entry 1ko3;
Garcia-Saez et al., 2008). The final structure was obtained by
manual model optimization in WinCoot according to the
2Fo  Fc and Fo  Fc electron-density maps and several
refinement cycles using PHENIX (Emsley et al., 2010; Adams
et al., 2010). Translation/libration/screw (TLS) parameters
were used in the refinement process. Alternative rotamers
were manually modelled in WinCoot and refined as imple-
mented in PHENIX. Noncrystallographic symmetry (NCS)
restraints were not used during the refinement. For all Zn2+
and Cl ions, anisotropic B factors and occupancies were
refined by PHENIX. 5% of the X-ray data were used for Rfree
cross-validation. Refinement statistics are shown in Table 3.
The PyMOL Molecular Graphics System v.1.4.1 (Schrödinger)
and LIGPLOT were used to generate illustrations and to
visualize interactions (Wallace et al., 1995). The class B
-lactamase numbering system is used for the numbering of all
residues (Garau et al., 2004).
3. Results and discussion
3.1. Inhibition of VIM-2 by triazolylthioacetamides
In a previous study, we established a nitrocefin-based
enzyme-activity assay suitable to study the influence of inhi-
bitors on the activity of VIM-2 (Christopeit et al., 2015). This
research communications
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Table 2
Data collection.
Values in parentheses are for the outer shell.




Crystal-to-detector distance (mm) 297
Rotation range per image () 0.1
Total rotation range () 200
Exposure time per image (s) 0.4
Space group C2
a, b, c (Å) 100.62, 79.25, 67.20
, ,  () 90.0, 90.0, 130.5
Resolution range (Å) 38.25–1.50 (1.52–1.50)
No. of unique reflections 63893
Multiplicity 3.7 (3.6)
Completeness (%) 99.1 (93.3)
Rmerge (%) 4.8 (30.9)
Mean hI/(I)i 18.8 (4.3)




Final Rwork (%) 13.55
Final Rfree (%) 16.55
No. of non-H atoms
Protein 3901 (chains A and B)
Ions 6 Zn2+, 6 Cl





Average B factors (Å2)
Protein 17.6
Ion 15.9
Compound 1 (occupancy) 21.3 (0.99/0.98)
Water 32.1
Ramachandran plot
Most favoured (%) 98.3
Allowed (%) 1.5
Figure 1
Structures of the tested triazolylthioacetamide inhibitors: compound 1
(a), compound 2 (b) and compound 3 (c).
Figure 2
Dose–response curve for the inhibition of VIM-2 by compound 1.
assay was used to determine the inhibition potency of three
substituted triazolylthioacetamides (Fig. 1). All three
compounds have previously been reported as inhibitors of
different MBLs (Yang et al., 2015; Zhang et al., 2014).
However, only compound 1 showed clear inhibition of VIM-2,
whereas compounds 2 and 3 had no influence on the enzyme
activity at concentrations of up to 100 mM (data not shown).
To determine the IC50 for compound 1, the inhibition at
different concentrations was measured and the data were
fitted to a dose–response curve (Fig. 2). The IC50 was calcu-
lated to be 20 mM (pIC50 = 4.71  0.04).
3.2. DMSO-free co-crystallization of VIM-2 with compound 1
We have previously reported crystal structures of VIM-2 in
complex with small fragments (Christopeit et al., 2015). These
complex structures were obtained by solving the fragments
in DMSO and soaking them into native VIM-2 crystals.
However, the soaking time was limited by the negative influ-
ence of DMSO on the crystal quality and soaking was not
successful for compound 1. Furthermore, adding compound 1
directly to the reservoir or protein solution prevented crystal
formation, most likely owing to the high DMSO concentra-
tion. Therefore, a DMSO-free co-crystallization strategy was
explored in which the reservoir wells were pre-coated with
compound 1 (Fig. 3). To achieve the pre-coating, the dissolved
inhibitor was added to the reservoir wells and the DMSO
was removed by evaporation. Afterwards, the inhibitor was
redissolved in the reservoir solution, which was then used to
set up the crystallization experiments. The structures obtained
from crystals prepared by the DMSO-free co-crystallization
showed additional electron density in the active site of VIM-2
corresponding to compound 1. Although the pre-coating of
sitting-drop wells with ligands has been reported before
(Gelin et al., 2015), to our knowledge the pre-coating of
reservoir wells with ligands has not been used for co-crystal-
lization.
3.3. Complex structure of VIM-2 with compound 1
The crystal structure of VIM-2 in complex with compound 1
was solved by molecular replacement to a resolution of 1.5 Å.
The complex crystallized in space group C2, with two protein
molecules in the asymmetric unit (Fig. 4). Details of the
refinement statistics are shown in Table 3. The overall
completeness of the data set was 99.1%, with a multiplicity of
3.7 and an Rmerge of 4.8%. The overall structures of the two
VIM-2 molecules in the asymmetric unit were similar, with an
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Figure 3
Strategy for DMSO-free co-crystallization of VIM-2 with compound 1.
After adding compound 1 to the reservoir well, the DMSO was
evaporated and compound 1 was redissolved in the reservoir solution.
The reservoir solution was mixed with the protein solution to set up
sitting-drop experiments.
Figure 4
Ribbon diagram of the two VIM-2 molecules in the asymmetric unit. Helices are shown in red (chain A) or salmon (chain B) and -strands are shown in
yellow (chain A) or purple (chain B). The inhibitor bound to the active site is shown in stick representation with atom-type colouring and C atoms
depicted in cyan. Zn2+ ions are shown as orange spheres and Cl ions as dark blue spheres.
r.m.s. deviation of 0.36 Å for the C atoms (WinCoot; Emsley
et al., 2010).
As is typical for MBLs, VIM-2 was folded in an /
sandwich. Two Zn2+ ions were observed in the active site of
the enzyme, where Zn1 was coordinated by His116, His118
and His196, and Zn2 was coordinated by Asp120, Cys221 and
His263. Between the two symmetry mates, a third Zn2+ ion was
located, which has been observed before and is normally
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Figure 5
OMIT maps (a, b), final density maps (c, d) and crystal structures (e, f ) of compound 1 bound to the active site of VIM-2. The complex crystallized with
two copies in the asymmetric unit (chains A and B). C atoms of compound 1 are depicted in blue and VIM-2 C atoms in green. Water molecules are
shown in red and Zn2+ ions in orange. The OMIT Fo  Fc maps are shown in dark green at 2.25. The final 2Fo  Fc electron-density maps around the
ligand are shown in blue at 1. The final Fo Fc difference density maps around the ligand are shown at 4 (light green) and4 (red). The interactions
were analysed using LIGPLOT (g, h). Hydrogen bonds are shown as red dashed lines and interatomic distances are given in Å. Hydrophobic
interactions are indicated by red arcs.
considered to be a crystallographic artefact. The overall
protein structure and the coordination of the Zn2+ ions, as well
as the Zn–ligand and Zn–Zn distances, were in agreement with
previously published VIM-2 structures (Garcia-Saez et al.,
2008; Aitha et al., 2014; Christopeit et al., 2015; Yamaguchi et
al., 2007).
In the active site of both VIM-2 molecules, additional
electron density corresponding to a chloride ion was observed.
The ions showed high occupancy, and the B factors of 17.3 and
20.5 Å2 for chains A and B, respectively, were consistent with
the average B factor of the protein (Table 3). Although the
chloride ions were in proximity to the bound inhibitor, they
showed no direct interaction. The ions were coordinated by
the backbone N atom of Asp119, the side-chain N atom of
Asn165 and one or three water molecules. To our knowledge,
chloride ions at this position in the active site of VIM-2 have
not been observed before. However, it is not clear whether the
chloride ion has any biological relevance or whether it is a
crystallographic artefact.
The experimental electron-density map clearly showed
additional density corresponding to compound 1 in the active
site of both VIM-2 molecules in the asymmetric unit (Fig. 5).
The carboxyl group of the inhibitor interacts with Zn2 and
forms hydrogen bonds to two water molecules and the back-
bone O atom of Asn233. Similar interactions have been
observed before for fragments binding to the active site of
VIM-2 (Christopeit et al., 2015). The importance of this
interaction for inhibitor binding is reflected by the fact that
replacing the carboxyl group by a hydroxide group, as in
compound 2, or replacing the benzoic acid moiety by an
4-pyridyl moiety, as in compound 3, resulted in a strong
reduction in the inhibitory potency. The triazole ring of
compound 1 interacted with both zinc ions and replaced the
hydroxide molecule that normally bridges the two zinc ions in
the native structure of VIM-2 (Christopeit et al., 2015; Garcia-
Saez et al., 2008). Furthermore, the benzothiazole ring formed
parallel – stacking with Phe61 and T-shaped – stacking
with Trp87. Compared with our previously published struc-
tures of native VIM-2 and of VIM-2 in complex with frag-
ments (Christopeit et al., 2015), the binding of compound 1
induced a flip of the backbone and a 180 flip of the side chain
of Trp87 (Fig. 6). Penicillins are well known substrates of
VIM-2 and several of them have bulky hydrophobic groups,
e.g. ampicillin or benzylpenicillin (Poirel et al., 2000). The
interactions involved in the binding of different substrates to
VIM-2 are not exactly known and no crystal structures in
complex with these substrates have been reported. However,
the structure of New Delhi metallo--lactamase 1 (NDM-1) in
complex with hydrolysed benzylpenicillin has been reported
(King et al., 2012). This structure shows that the bulky
hydrophobic group of benzylpenicllin forms similar inter-
actions with the conserved residue Trp87 in NDM-1 as
compound 1 forms with Trp87 in VIM-2 (Fig. 7). Hence, it is
likely that the binding of substrates with bulky hydrophobic
groups to the active site of VIM-2 also induces the same
conformational changes of Trp87 as compound 1.
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Figure 6
Structural alignment of a native VIM-2 structure (purple; PDB entry
5acu; Christopeit et al., 2015), the VIM-2 structure in complex with
compound 1 (green) and the VIM-2 structure in complex with a fragment
(grey; PDB entry 5acx; Christopeit et al., 2015). The protein backbones
are shown as ribbon cartoons. Zinc ions are shown as orange spheres and
Trp87, compound 1 and the fragment are shown as sticks.
Figure 7
Structural alignment of the VIM-2 structure in complex with compound 1
(green) and a structure of NDM-1 bound to hydrolysed benzylpenicillin
(purple; PDB entry 4eyf; King et al., 2012). The protein backbones are
shown as ribbon cartoons. Zinc ions are shown as orange spheres and
Trp87, compound 1 and the fragment are shown as sticks.
4. Conclusion
In this study, compound 1 was identified as an inhibitor of the
MBL VIM-2. The determined IC50 was in the low-micromolar
range and hence needs to be further optimized. However,
compound 1 has already been reported as an inhibitor of the
MBLs ImiS and CcrA, and therefore is an interesting starting
point for the development of broad-spectrum MBL inhibitors
(Yang et al., 2015). Furthermore, the crystal structure of
compound 1 in complex with VIM-2 is presented. To our
knowledge, this is the first structure of a triazolylthioacet-
amide inhibitor bound to an MBL. The detailed information
about the interactions involved in the binding of the inhibitor
and the induced conformational changes of the conserved
residue Trp87 will help to further optimize triazolylthioacet-
amide inhibitors and improve rational drug design targeting
MBLs.
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Garau, G., Garcı́a-Sáez, I., Bebrone, C., Anne, C., Mercuri, P.,
Galleni, M., Frère, J.-M. & Dideberg, O. (2004). Antimicrob. Agents
Chemother. 48, 2347–2349.
Garcia-Saez, I., Docquier, J.-D., Rossolini, G. M. & Dideberg, O.
(2008). J. Mol. Biol. 375, 604–611.
Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M. R.,
Appel, R. D. & Bairoch, A. (2005). The Proteomics Protocols
Handbook, edited by J. M. Walker, pp. 571–607. Totowa: Humana
Press.
Gelin, M., Delfosse, V., Allemand, F., Hoh, F., Sallaz-Damaz, Y.,
Pirocchi, M., Bourguet, W., Ferrer, J.-L., Labesse, G. & Guichou,
J.-F. (2015). Acta Cryst. D71, 1777–1787.
Kabsch, W. (2010). Acta Cryst. D66, 125–132.
King, D. T., Worrall, L. J., Gruninger, R. & Strynadka, N. C. J. (2012).
J. Am. Chem. Soc. 134, 11362–11365.
Lucasti, C., Vasile, L., Sandesc, D., Venskutonis, D., McLeroth, P.,
Lala, M., Rizk, M. L., Brown, M. L., Losada, M. C., Pedley, A.,
Kartsonis, N. A. & Paschke, A. (2016). Antimicrob Agents
Chemother. 60, 6234–6243.
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D.,
Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674.
Mueller, U., Darowski, N., Fuchs, M. R., Förster, R., Hellmig, M.,
Paithankar, K. S., Pühringer, S., Steffien, M., Zocher, G. & Weiss,
M. S. (2012). J. Synchrotron Rad. 19, 442–449.
Poirel, L., Naas, T., Nicolas, D., Collet, L., Bellais, S., Cavallo, J. D. &
Nordmann, P. (2000). Antimicrob. Agents Chemother. 44, 891–
897.
Wallace, A. C., Laskowski, R. A. & Thornton, J. M. (1995). Protein
Eng. 8, 127–134.
World Health Organization (2014). Antimicrobial Resistance: Global
Report on Surveillance. Geneva: World Health Organization. http://
www.who.int/drugresistance/documents/surveillancereport/en/.
Yamaguchi, Y., Jin, W., Matsunaga, K., Ikemizu, S., Yamagata, Y.,
Wachino, J., Shibata, N., Arakawa, Y. & Kurosaki, H. (2007). J.
Med. Chem. 50, 6647–6653.
Yang, S.-K., Kang, J. S., Oelschlaeger, P. & Yang, K.-W. (2015). ACS
Med. Chem. Lett. 6, 455–460.
Zhai, L., Zhang, Y.-L., Kang, J. S., Oelschlaeger, P., Xiao, L., Nie, S.-S.
& Yang, K.-W. (2016). ACS Med. Chem. Lett. 7, 413–417.
Zhang, Y.-L., Yang, K.-W., Zhou, Y.-J., LaCuran, A. E., Oelschlaeger,
P. & Crowder, M. W. (2014). ChemMedChem, 9, 2445–2448.
research communications
Acta Cryst. (2016). F72, 813–819 Christopeit et al.  VIM-2 in complex with a triazolylthioacetamide inhibitor 819
